National Cancer Institute, France   Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4
Founded: Paris France (2005)

Organization Overview

First Clinical Trial
2005
NCT00421317
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

French National Cancer Institute | National Cancer Institute, France | The French National Cancer Institute

Active Ingredients

Drugs in Phase 4 Trials (3)

cabozantinib (cometriq) (1 trial)

ropivacaine (naropin) (1 trial)

sunitinib (sutent) (3 trials)

Drugs in Phase 3 Trials (37)

acetylsalicylic acid (aspirin) (1 trial)

atezolizumab (Tecentriq) (3 trials)

atorvastatin (lipitor) (1 trial)

busulfan (Myleran) (1 trial)

carboplatin (paraplatin) (4 trials)

cetuximab (erbitux) (3 trials)

cisplatin (platinol) (6 trials)

cyclophosphamide (cytoxan) (4 trials)

cytarabine (cytosar-u) (1 trial)

daunorubicin (cerubidine) (1 trial)

doxorubicin (Doxil) (1 trial)

durvalumab (imfinzi) (3 trials)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (2 trials)

fluorouracil (efudex) (8 trials)

gemtuzumab ozogamicin (mylotarg) (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

hydroxyurea (hydrea) (1 trial)

ifosfamide (ifex) (2 trials)

indocyanine green (ic-green) (1 trial)

interferon alpha-1 (1 trial)

leucovorin (7 trials)

medroxyprogesterone (provera) (1 trial)

megestrol (megace) (1 trial)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (2 trials)

nivolumab (opdivo) (3 trials)

olaparib (lynparza) (4 trials)

oxaliplatin (eloxatin) (6 trials)

patent blue v dye (1 trial)

pembrolizumab (keytruda) (3 trials)

pemetrexed (alimta) (1 trial)

ruxolitinib (jakafi) (1 trial)

thyrotropin (Thyropar) (1 trial)

tinzaparin (Innohep) (1 trial)

trastuzumab (herceptin) (1 trial)

zoledronic acid (zometa) (1 trial)

Drugs in Phase 2 Trials (44)

177lu-dota0-tyr3-octreotate (Dotatate) (1 trial)

autologous hematopoietic stem cells (1 trial)

bevacizumab (avastin) (3 trials)

buparlisib (1 trial)

cabazitaxel (jevtana kit) (1 trial)

capecitabine (xeloda) (1 trial)

crizotinib (xalkori) (1 trial)

docetaxel (taxotere) (3 trials)

everolimus (zortress) (2 trials)

fulvestrant (faslodex) (1 trial)

furosemide (lasix) (1 trial)

gedatolisib (1 trial)

ibrutinib (imbruvica) (1 trial)

imatinib (gleevec) (1 trial)

iobenguane sulfate i-131 (2 trials)

irinotecan (Camptosar) (4 trials)

lapatinib (tykerb) (1 trial)

lenalidomide (revlimid) (1 trial)

m1774 (1 trial)

medi5752 (2 trials)

metformin (glucophage) (1 trial)

mk-1775 (1 trial)

msk-2206 (1 trial)

nilotinib (tasigna) (1 trial)

paclitaxel (taxol) (2 trials)

pazopanib (votrient) (3 trials)

pexastimogene devacirepvec (1 trial)

ralimetinib (2 trials)

Raltitrexed (Tomudex) (1 trial)

ribociclib (kisqali) (1 trial)

sargramostim (leukine) (1 trial)

siremadlin (1 trial)

sorafenib (nexavar) (1 trial)

spartalizumab (1 trial)

spironolactone (aldactone) (1 trial)

streptozotocin (1 trial)

tamoxifen (nolvadex) (1 trial)

temozolomide (temodar) (6 trials)

topotecan (hycamtin) (2 trials)

tremelimumab (Imjudo) (1 trial)

ucpvax (1 trial)

vemurafenib (zelboraf) (1 trial)

vinorelbine (navelbine) (2 trials)

vistusertib (1 trial)

Drugs in Phase 1 Trials (4)

aldesleukin (Proleukin) (1 trial)

allogeneic natural killer cells (1 trial)

c13 n15 valine (1 trial)

cidofovir (vistide) (1 trial)

Drugs in Other Trials (5)

fluorothymidine (1 trial)

nicotine (nicorette) (1 trial)

octreotide (sandostatin) (1 trial)

sulfur hexafluoride lipid-type a microspheres (Lumason) (1 trial)

vatalanib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ascites (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Islet Cell (Phase 2)

Carcinoma, Neuroendocrine (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Renal Cell (Phase 4)

Carcinoma, Squamous Cell (Phase 2)

Carotid Body Tumor (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Disease Progression (Phase 2)

Endometrial Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 2)

Head and Neck Neoplasms (Phase 3)

Hematologic Neoplasms (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Melanoma (Phase 2)

Microsatellite Instability (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neoplasms, Second Primary (Phase 2)

Neoplastic Cells, Circulating (Phase 2)

Nervous System Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Osteosarcoma (Phase 3)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Paraganglioma (Phase 2)

Penile Neoplasms (Phase 2)

Pheochromocytoma (Phase 2)

Polycythemia (Phase 3)

Polycythemia Vera (Phase 3)

Preleukemia (Phase 2)

Prostatic Neoplasms (Phase 3)

Recurrence (Phase 3)

Sarcoma (Phase 2)

Skin Neoplasms (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Thromboembolism (Phase 3)

Thyroid Diseases (Phase 4)

Thyroid Neoplasms (Phase 4)

Triple Negative Breast Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Venous Thromboembolism (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 67
  • # of Trial APIs: 93